Zusammenfassung
Ca. 90% aller malignen Melanome kommen derzeit als Primärtumor ohne erkennbare Metastasierung zur ersten Diagnose [9]. Die 10-Jahres-Überlebensrate im Gesamtkollektiv beträgt ca. 75–80%. Die wichtigsten prognostischen Faktoren beim primären malignen Melanom sind nach neueren multizentrischen Studien [9, 10] folgende:
-
Die vertikale Tumordicke nach Breslow am histologischen Präparat (≤ 0,75 mm: ca. 97% 10-Jahres-Überlebensrate; 0,76–1,5 mm: ca. 90% 10-JÜR; 1,5–4 mm ca. 65% 10-JÜR; >4 mm: ca. 50% 10-JÜR)
-
der Invasionslevel nach Clark (insb. die Unterscheidung zwischen Level II und III)
-
der histologische Typ (ungünstig: primär noduläre Melanome und akrolentiginöse Melanome)
-
das Geschlecht (signifikant schlechtere Prognose für Männer) und
-
die Tumorlokalisation (ungünstige Prognose für oberen Stamm, Oberarme, Hals und behaarten Kopf).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Osterlind A, Möller Jensen O (1986) Trends in incidence of malignant melanoma of the skin in Denmark 1943–1982. Recent Results Cancer Res 102: 8–17
Garbe C, Thieß S, Nürnberger F et al. (1991) Incidence and mortality of malignant melanoma in Berlin (West) from 1980 to 1986. Acta Derm Venerol (Stockh) 71: 506–511
MacKie RM, Freudenberger T, Aitchison TC (1989) Personal risk-factor chart for cutaneous melanoma. Lancet ii: 487–490
Garbe C (1992) Sonne und malignes Melanom. Hautarzt 43: 251–257
Garbe C, Orfanos CE (1992) Epidemiology of malignant melanoma in Central Europe. Risk factors and prognostic predictors. Pigment Cell Res 5 (Suppl 2): 285–294
Garbe C, Weiß J, Krüger S et al. (1993) The German Melanom Registry and environmental risk factors implied. Recent Results Cancer Res 128: 69–89
Garbe C, Büttner P, Weiß J et al. (1994) Risk factors for developing cutaneous melanoma and criteria for identification of persons at risk. Multicenter Case Control Study of the German Central Malignant Melanoma Registry. J Invest Dermatol 102: 695–699
Garbe C, Büttner P, Weiß J et al. (1994) Associated factors to the prevalence of > 50 common melanocytic nevi, atypical melanocytic nevi and actinic lentigines. Multicenter Case Control Study of the German Central Malignant Melanoma Registry. J Invest Dermatol 102: 700–705
Garbe C, Büttner P, Bertz J et al. (1990) Die Prognose des primären malignen Melanoms — eine multizentrische Studie an 5093 Patienten. In: Orfanos CE, Garbe C (Hrsg.): Das maligne Melanom der Haut. Zuckschwerdt, München, S 41–59
Ketcham AS, Moffat FL, Balch CM (1992) Classification and staging. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds) Cutaneous melanoma. JB Lippincott, Philadelphia, pp 165–187
Orfanos CE, Döring C. Malignes Melanom 1983: Eine aktuelle Bestandsaufnahme. Klassifikation, prognostische Faktoren, Behandlungsrichtlinien. Z Hautkr 58: 881–900
Häffner AC, Garbe C, Büttner P, Orfanos CE, Rassner G, Burg G (1992) The prognosis of primary and metastasizing melanoma. An evaluation of the TNM classification in 2495 patients and proposals for their revision. Br J Cancer 66: 856–861
Orfanos CE, Jung HG, Rassner G, Wolff HH, Garbe C (1994) Stellungnahme und Empfehlungen der Kommission Malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des Malignen Melanoms der Haut — Stand 1993/94. Hautarzt 45: 285–291
Ackerman AB, Scheiner AM (1983) How wide and deep is wide and deep enough? A critique of surgical practice in excision of primary cutaenous malignant melanoma. Human Pathol 14: 743–744
Schmoeckel C, Bockelbrink A, Bockelbrink H, Braun-Falco 0 (1983) Low-and high-risk malignant melanoma. III. Prognostic significance of the resiction margin. Eur J Cancer Clin Oncol 19: 245–249
Veronesi U, Cascinell N, Adamus J et al. (1988) Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 318: 1159–1162
Garbe C, Stadler R, Orfanos CE (1989) Lokalrezidive und Metastasierung bei dünnen malignen Melanomen (>-1 mm). Hautarzt 40: 337–343
Landthaler M, Braun-Falco 0 (1989) Zur Therapie des malignen Melanoms im Stadium I. Offene Fragen und Empfehlungen. Onkologie 12: 269–272
Seebacher C, Heubaum F, Kuster P, Steinert W, Koch R (1990) Vergleichende Analyse in Narkose und Lokalanästhesie operierter maligner Melanome der Haut. Hautarzt 41: 137–141
Veronesi U, Adamus J, Bandiera DC et al. (1982) Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 49: 2420–2430
Balch CM, Milton GW, Cascinelli N, Sim HF (1992) Elective Lymph node dissection: pros and cons. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds) Cutaneous melanoma. JB Lippincott, Philadelphia, pp 345–366
Drepper H, Köhler CO, Bastian B et al. (1993) Benefit of elective node dissection in subgroups of melanoma patients — results of a multicenter study in 3616 patients. Cancer 72: 741–749
Drepper H, Köhler CO, Bastian B et al. (1994) Prognosevorteil für definierte Risikogruppen durch die Lymphknotendissektion. Langzeitstudie an 3616 Melanompatienten. Hautarzt 45: 615–622
Panizzon R, Alber R, Schnyder UW (1990) Die dermatologische Radiotherapie des Melanoms der Haut mit besonderer Berücksichtigung des Lentigo-maligna Melanoms. In Orfanos CE, Garbe C C (Hrsg) Das maligne Melanom der Haut, Zuckschwerdt Verlag, München, S 232–235
Veronesi U, Adamus J, Aubert et al. (1982) A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. New Engl J Med 307: 913–916
Lejeune EJ (1987) Phase III adjuvant studies in operable malignant melanoma (review). Anticancer Res 7: 701–706
Hauschild A, Sterry W (1992) Adjuvante Therapie des malignen Melanoms. Dtsch Med Wochenschr 117: 303–306
Beiteke U, Ruppert P, Garbe C et al. (1993) Adjuvante Therapie des primären malignen Melanoms mit natürlichem humanen Interferon-beta. Signifikanter Überlebensvorteil bei 96 behandelten Patienten im Vergleich zu 288 unbehandelten Symptomenzwillingen. Hautarzt 44: 365–371
Tilgen W (1994) Adjuvante und palliative Therapie des Melanoms. Eine Standortbestimmung. Chirurg 65: 153–163
Ames FC, Balch CM, Reintgen D (1992) Local recurrences and their management. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds) Cutaneous melanoma. JB Lippincott, Philadelphia, pp 287–294
Singletary SE, Balch CM (1992) Recurrent regional metastases and their management. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds) Cutaneous melanoma. JB Lippincott, Philadelphia, pp 427–435
Czarnetzki BM, Aragon V, Bröcker EB et al. (1986) Adjuvante Polychemotherapie zusätzlich zur radikalen operativen Behandlung regionaler Lymphknotenmetastasen beim malignen Melanom. Dt Med Wschr 11: 732–736
Garbe C, Guenther-Eymann K, Stadler R et al. (1988) Adjuvante Chemotherapie des malignen Melanoms mit DTIC. Wirkungslosigkeit im Stadium I, mögliche Verbesserung der Überlebensprognose im Stadium II b. Hautarzt 39: 205–212
Fiedler H, Hetschko I, Wohlrab W, Wozniak KD, Lübbe D, Taube KM (1990) Ergebnisse einer randomisierten Polychemotherapiestudie beim malignen Melanom. Hautarzt 41: 369–374
Saba HI, Cruse CW, Wells KE, Klein CJ, Reitgen DS (1992) Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a university of South Florida and H. Lee Moffitt Melanoma Center Study. Ann Plast Surg 28: 60–64
Retasas S, Quigley M, Pectasides D, Macrae K, Henry K (1994) Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival. Cancer 73: 2119–2130
Pectasides D, Alevizakos N, Bafaloukos D et al. (1994) Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma. Am J Clin Oncol 17: 55–59
Cascinelli N, Bufalino R, Morabito A, Mackie R (1994) Results of adjuvant interferon study in WHO melanoma programme. Lancet 343: 913–914
Mitchell MS, Harel W, Kan Mitchell J et al. (1993) Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action. Ann N Y Acad Sci 690: 153–166
Garbe C, Taud W, Karg Ch, Orfanos CE (1990) Nachsorge des metastasierenden malignen Melanoms. In: Orfanos CE, Garbe C (Hrsg): Das maligne Melanom der Haut. Zuckschwerdt, München, S 316–324
Karakousis CP, Velez A, Driscoll DL, Takita H (1994) Metastasectomy in malignant melanoma. Surgery 115: 295–302
Houghton AN, Legha S, Bajorin DF (1992) Chemotherapy for metastatic melanoma. In Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds) Cutaneous melanoma. JB Lippincott, Philadelphia, pp 498–508
Garbe C, Kreuser ED, Zouboulis CC, Stadler R, Orfanos CE (1992) Combined treatment of metastatic melanoma with interferons and cytotoxic drugs. Sem Oncol 19 (Suppl 4): 63–69
Garbe C (1993) Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 3: 291–299
Constanzi JJ, Vaitkevicius VK, Quagliana JM et al. (1975) Combination chemotherapy for disseminated malignant melanoma. Cancer 35: 342–346
Carter RD, Krementz ET, Hill GJ et a1. (1976) DTIC (NSC-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065). Cancer Treat Rep 60: 601–609
Constanzi JJ, Fletcher WS, Balcerzak SP et al. (1984) Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. Cancer 53: 833–836
Seigler HF, Lucas VS Jr, Pickett NJ et al. (1980) DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer 46: 2346–2348
Ahn SS, Giuliano A, Kaiser L et al. (1983) The limited role of BOLD chemotherapy for disseminated malignant melanoma. Proc Soc Clin Oncol 2:228, C-893
Jose DG, Minty CCJ, Hillcoat BL (1985) Treatment of patients with disseminated malignant melanoma with bleomycin, oncovin, lomustine and DTIC (BOLD). First international conference on skin melanoma, may 6–9, Venice, abstract 151
York RM, Foltz AT (1988) Bleomycin, vincristine, lomustine, and DTIC chemotherapy for malignant melanoma. Cancer 61: 2183–2186
The Prudente Foundation Melanoma Study Group (1989) Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). Cancer 63: 1676–1680
Gundersen S (1987) Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study. Cancer Treat Rep 71: 997–999
Verschraegen CF, Kleeberg UR, Mulder J et al. (1988) Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. Cancer 62: 1061–1065
Legha SS, Ring S, Papadopoulos N et al. (1989) A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) vor metastatic melanoma. Cancer 64: 2024–2029
Del Prete SA, Maurer LH, O’Donnell J et al. (1984) Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68: 1403–1405
Richards JM, Gilewski TA, Ramming K et al. (1992) Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer 69: 427–429
Saba HL, Cruse CW, Wells KE, Klein CJ, Reintgen DS (1992) Treatment of stage IV malignant melanoma with a platinol based combination chemotherapy regiment: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Ann Plast Surg 28: 65–69
Saba HI, Klein CJ, Reintgen DS (1993) Management of advanced stage IV metastatic melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Proc Annu Meet Am Soc Clin Oncol 121: A1359
McClay EF, Mastrangelo MJ, Berd D, Bellet RE (1992) Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 50: 553–556
Jacquillat C, Khayat D, Banzet P et al. (1990) Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol 25: 263–266
Hersey P, McLeod RC, Thomson DB (1989) Phase I/II study of tolerability and efficacy of recombinant interferon (Roferon) with dacarbazine (DTIC) in advanced malignant melanoma. J Interferon Res 9 (Suppl 2): 118
Kerr R, Pippen P, Mennel R, Jones S (1989) Treatment of metastatic malignant melanoma with a combination of interferon-alpha-2a (ifn-alpha-2a, Roferon) and dacarbazine (DTIC). Proc Annu Meet Am Soc Clin Oncol 8: A1122
Bajetta E, Negretti E, Giannotti B et al. (1990) Phase II study of interferon-alpha-2a and dacarbazine in advanced melanoma. Am J Clin Oncol 13: 405–409
Breier S, Pensel R, Roffe C et al. (1990) High dose DTIC with recombinant human interferon alpha-2b (rhifn2b) for the treatment of metastatic malignant melanoma (MMM). Proc Annu Meet Am Soc Clin Oncol 9: A1090
Mulder NH, Schraffordt-Koops H, Sleijfer DT et al. (1990) Dacarbazine and alpha-interferon for disseminated malignant melanoma. Proc Annu Meet Am Soc Clin Oncol 9: A1083
Falkson CI, Falkson G, Falkson HC (1991) Improved results with the addition of recombinant interferon alpha-2b to dacarbazine in treatment of patients with metastatic malignant melanoma. J Clin Oncol 9: 1403–1408
Bajetta E, Di Leo A, Zampino EG et al. (1994) Multicenter randomized trial of dacarbazine alone or in combination with different doses and schedules of interferon alpha-2a in the treatment of advanced melanoma. J Clin Oncol 12: 806–811
Thomson D, Adena M, McLeod GRC et al. (1992) Interferon-2a (IFN) does not improve response or survival when added to dacarbazine (DTIC) in metastatic melanoma: Results of a multi-institutional Australian randomized trial QMP8704. Proc Annu Meet Am Soc Clin Oncol 11: A1177
Schuchter L, McGuire WP, Wohlganger J, Redden T (1989) Sequential treatment of metastatic melanoma with interferon-alpa (IFN) plus cis-platinum (CDDP). Proc Annu Meet Am Soc Clin Oncol 8: A1120
Oratz R, Dugan M, Walsh C et al. (1989) Phase II trial of r-alpha 2b-interferon (IFN) and cisplatin (CDDP) in metastatic malignant melanoma (MM). Proc Annu Meet Am Soc Clin Oncol 8:A1123
Richner J, Cerny T, Joss RA et al. (1990) A phase II study of continuous sc alpha-2b interferon (IFN) combined with cisplatin (CDDP) in advanced malignant melanoma (MM). Proc Annu Meet Am Soc Clin Oncol 9: A1085
Margolin KA, Doroshow JH, Akman SA et al. (1992) Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma. J Clin Oncol 10: 1574–1578
Gundersen S, Flokkmann A (1989) Interferon in combination with vinblastine in advanced malignant melanoma. A phase I—II study. Cancer 64: 1617–1619
Kellokumpu-Lehtinen P, Nordman E, Toivanen A (1989) Combined interferon and vinblastine treatment of advanced melanoma: Evaluation of the treatment results and the effects of treatment of immunological functions. Cancer Immunol Immunother 28: 213–217
Smith KA, Green JA, Eccles JM (1992) Interferon alpha 2a and vindesine in the treatment of advanced malignant melanoma. Eur J Cancer 28: 438–441
Garbe C, Zouboulis CC, Stadler R et al. (1993) Prolongation of life in stage IV malignant melanoma by combined treatment with rIFN-a-2a and vindesine. Pigment Cell Res 6: 278
Vorobiof DA, Bezwoda WR, Ariad S (1993) Vindesine plus interferon a2b vs IFN a2b vs vindesine in the treatment of advanced melanoma. Proc Annu Meet Am Soc Clin Oncol 12: A1388
Rosenberg SA, Lotze MT, Yang JC et al. (1989) Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474–485
Dillman RO, Oldham RK, Barth NM et al. (1990) Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial. J Natl Cancer Inst 82: 1345–1349
Flaherty LE, Redman BG, Chabot GG et al. (1990) A phase I—II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma. Cancer 65: 2471–2477
Dummer R, Becker JC, Kahlhammer U et al. (1991) Combined chemo-and immunotherapy using dacarbazine and continuous infusion of interleukin 2 in metastatic malignant melanoma. Results of a phase II clinical trial. Eur J Dermtol 1: 201–205
Demchak PA, Mier JW, Robert NJ et al. (1990) Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 9: 1821–1830
Hamblin TJ, Davies B, Sadullah S, Oskam R, Palmer P, Franks CR (1991) A phase II study of the treatment of metastatic malignant melanoma with a combination of dacarbazine, cisplatin, interleukin-2(IL-2) and alfa-interferon (IFN). Proc Annu Meet Am Soc Clin Oncol 10:A 1029
Legha S, Plager C, Ring S, Eton O et al. (1992) A phase II study of biochemotherapy using interleukin-2 (IL-2) + Interferon alfa-2a (IFN) in combination with cisplatin (C) vinblastine (V) and DTIC (D) in patients with metastatic melanoma. Proc Annu Meet Am Soc Clin Oncol 11: A1179
Richards JM, Mehta N, Ramming K, Skosey P (1992) Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10: 1338–1343
Richards J, Mehta N, Schroeder L, Dordal A (1992) Sequential chemotherapy/ immunotherapy for metastatic melanoma. Proc Annu Meet Am Soc Clin Oncol 11:A 1189
Khayat D, Borel C, Tourani JM et al. (1993) Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 11: 2173–2180
Kirchner H, Lopez Haenninen M, Fenner M et al. (1993) Chemoimmunotherapy of advanced malignant melanoma with carboplatin and DTIC followed by subcutaneous interleukin-2 and interferon-alpha. Proc Annu Meet Am Soc Clin Oncol 12: A1356
Atkins MB, O’Boyle KR, Sosman JA et al. (1994) Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 12: 1553–1560
Ron IG, Mordish Y, Eisenthal A et al. (1994) A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma. Cancer Immunol Immunother 38: 379–384
D’Hoedt B, Stroebel W, Stutte H, Rassner G (1990) Nachsorge des malignen Melanoms an der Tübinger Hautklinik. In: Orfanos CE, Garbe C (Hrsg): Das maligne Melanom der Haut. Zuckschwerdt, München, S 304–311
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Garbe, C. (1995). Malignes Melanom. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10494-1_32
Download citation
DOI: https://doi.org/10.1007/978-3-662-10494-1_32
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-58586-2
Online ISBN: 978-3-662-10494-1
eBook Packages: Springer Book Archive